Table 2. Relationships between clinicolaboratory characteristics and mGPS.
| mGPS 0 n (%) | mGPS 1 n (%) | mGPS 2 n (%) | P- value a | |
|---|---|---|---|---|
| Sex | ||||
| Male | 1045 (90.3) | 60 (5.2) | 52 (4.5) | 0.036 |
| Female | 520 (94.0) | 18 (3.3) | 15 (2.7) | |
| Age (years) | ||||
| <65 | 831 (93.9) | 29 (3.3) | 25 (2.8) | 0.001 |
| ⩾65 | 723 (88.9) | 48 (5.9) | 42 (5.2) | |
| Body mass index (kg m−2) | ||||
| <18.5 | 212 (81.2) | 17 (6.5) | 32 (12.3) | <0.001 |
| 18.5–25 | 1059 (93.1) | 47 (4.1) | 32 (2.8) | |
| ⩾25 | 221 (94.8) | 11 (4.7) | 1 (0.4) | |
| Tumour location | ||||
| Upper third | 414 (90.0) | 22 (4.8) | 24 (5.2) | 0.069 |
| Middle third | 722 (93.5) | 29 (3.8) | 21 (2.7) | |
| Lower third | 421 (89.6) | 27 (5.7) | 22 (4.7) | |
| White cell count ( × 10 l−1) | ||||
| <11 | 1556 (92.5) | 70 (4.2) | 56 (3.3) | <0.001 |
| ⩾11 | 8 (29.6) | 8 (29.6) | 11 (40.7) | |
| Neutrophils ( × 109 l−1) | ||||
| <7.5 | 1498 (93.3) | 65 (4.0) | 42 (2.6) | <0.001 |
| ⩾7.5 | 19 (38.0) | 12 (24.0) | 19 (38.0) | |
| Lymphocytes ( × 109 l−1) | ||||
| <3 | 1458 (91.6) | 75 (4.7) | 59 (3.7) | 0.633 |
| ⩾3 | 59 (93.7) | 2 (3.2) | 2 (3.2) | |
| CEA (ng ml−1) | ||||
| ⩽5 | 1342 (93.6) | 56 (3.9) | 25 (2.4) | <0.001 |
| >5 | 184 (79.0) | 20 (8.6) | 29 (12.4) | |
| CA19-9 (ng ml−1) | ||||
| ⩽37 | 1299 (92.4) | 57 (4.1) | 50 (3.6) | 0.006 |
| >37 | 128 (84.8) | 12 (7.9) | 11 (7.3) | |
| Tumour stage | ||||
| I | 961 (96.4) | 30 (3.0) | 6 (0.6) | <0.001 |
| II | 177 (88.5) | 9 (4.5) | 14 (7.0) | |
| III | 219 (89.4) | 13 (5.3) | 13 (5.3) | |
| IV | 208 (77.6) | 26 (9.7) | 34 (12.7) | |
Abbreviations: CEA=carcinoembryonic antigen; mGPS=modified Glasgow prognostic score.
a
χ2 test.